Heterogeneous Response to Immunotherapy in a Patient with Tonsillar Squamous Cell Carcinoma Assessed by 18F-FDG PET/CT
Abstract
:Author Contributions
Funding
Informed Consent Statement
Conflicts of Interest
References
- Moskovitz, J.; Moy, J.; Ferris, R.L. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr. Oncol. Rep. 2018, 20, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Joo Hyun, O.; Lodge, M.A.; Wahl, R.L. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology 2016, 280, 576–584. [Google Scholar] [CrossRef] [Green Version]
- Decazes, P.; Bohn, P. Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications. Cancers 2020, 12, 371. [Google Scholar] [CrossRef] [Green Version]
- Champiat, S.; Dercle, L.; Ammari, S.; Massard, C.; Hollebecque, A.; Postel-Vinay, S.; Chaput, N.; Eggermont, A.M.; Marabelle, A.; Soria, J.-C.; et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin. Cancer Res. 2017, 23, 1920–1928. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crusz, S.M.; Tang, Y.Z.; Sarker, S.-J.; Prevoo, W.; Kiyani, I.; Beltran, L.; Peters, J.; Sahdev, A.; Bex, A.; Powles, T.; et al. Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Med. 2016, 14, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Canning, M.; Guo, G.; Yu, M.; Myint, C.; Groves, M.W.; Byrd, J.K.; Cui, Y. Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy. Front. Cell Dev. Biol. 2019, 7, 52. [Google Scholar] [CrossRef]
- Economopoulou, P.; Perisanidis, C.; Giotakis, E.I.; Psyrri, A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): Anti-tumor immunity and clinical applications. Ann. Transl. Med. 2016, 4, 173. [Google Scholar] [CrossRef] [Green Version]
- Cohen, E.E.W.; Bell, R.B.; Bifulco, C.B.; Burtness, B.; Gillison, M.L.; Harrington, K.J.; Le, Q.-T.; Lee, N.Y.; Leidner, R.; Lewis, R.L.; et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J. Immunother. Cancer 2019, 7, 184. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ranieri, G.; Marech, I.; Asabella, A.N.; Di Palo, A.; Porcelli, M.; Lavelli, V.; Rubini, G.; Ferrari, C.; Gadaleta, C.D. Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation. Int. J. Mol. Sci. 2017, 18, 1937. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Evangelista, L.; De Rimini, M.L.; Bianchi, A.; Schillaci, O. Immunotherapy and 18F-FDG PET/CT: Standardised procedures are needed. Clin. Transl. Imaging 2019, 7, 313–315. [Google Scholar] [CrossRef] [Green Version]
- Ferrari, C.; Asabella, A.N.; Merenda, N.; Altini, C.; Fanelli, M.; Muggeo, P.; De Leonardis, F.; Perillo, T.; Santoro, N.; Rubini, G. Pediatric Hodgkin Lymphoma. Medicine 2017, 96, e5973. [Google Scholar] [CrossRef] [PubMed]
- Lang, D.; Wahl, G.; Poier, N.; Graf, S.; Kiesl, D.; Lamprecht, B.; Gabriel, M. Impact of PET/CT for Assessing Response to Immunotherapy—A Clinical Perspective. J. Clin. Med. 2020, 9, 3483. [Google Scholar] [CrossRef] [PubMed]
- O, J.H.; Wahl, R.L. PERCIST in Perspective. Nucl. Med. Mol. Imaging 2017, 52, 1–4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wahl, R.L.; Jacene, H.; Kasamon, Y.; Lodge, M.A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J. Nucl. Med. 2009, 50, 122–150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Niccoli Asabella, A.; Nappi, A.G.; Trani, O.; Sardaro, A.; Rubini, G. Heterogeneous Response to Immunotherapy in a Patient with Tonsillar Squamous Cell Carcinoma Assessed by 18F-FDG PET/CT. Diagnostics 2021, 11, 348. https://doi.org/10.3390/diagnostics11020348
Niccoli Asabella A, Nappi AG, Trani O, Sardaro A, Rubini G. Heterogeneous Response to Immunotherapy in a Patient with Tonsillar Squamous Cell Carcinoma Assessed by 18F-FDG PET/CT. Diagnostics. 2021; 11(2):348. https://doi.org/10.3390/diagnostics11020348
Chicago/Turabian StyleNiccoli Asabella, Artor, Anna Giulia Nappi, Orsola Trani, Angela Sardaro, and Giuseppe Rubini. 2021. "Heterogeneous Response to Immunotherapy in a Patient with Tonsillar Squamous Cell Carcinoma Assessed by 18F-FDG PET/CT" Diagnostics 11, no. 2: 348. https://doi.org/10.3390/diagnostics11020348